A Phase II, Open-Label, Single Arm Trial to Assess the Efficacy and Safety of the Combination of Tisagenlecleucel and Ibrutinib in Mantle Cell Lymphoma (TARMAC)

This poster describes a clinical trial of tisagenlecleucel + ibrutinib that is currently recruiting in Australia. The trial allows very early recruitment of patients with MCL+genomic risk factors, or recruitment at first relapse. The goal is to improve safety and estimate response rates.